Track Envista Holdings Corporation — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Envista Holdings Corporation NVST · Stock Open Envista Holdings Corporation in new tab

24.49 USD
P/E
6.75
EPS
3.85
P/B
1.35
ROE
20.52
Beta
0.94
Target Price
28.92 USD
Loading chart...
Key Metrics
Earnings dateFeb. 4, 2027
P/E6.75
EPS3.85
Book Value19.27
Price to Book1.35
Debt/Equity51.40
% Insiders0.557%
Growth
Revenue Growth0.03%
Earnings Growth1.11%
Estimates
Forward P/E15.56
Forward EPS1.67
Target Mean Price28.92

DCF valuation

Model fair value for Envista Holdings Corporation (NVST)
Result
Sign in to run the valuation for NVST.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
13 analysts · consensus Buy · mean target 28.92 USD (low 23.00, high 32.00) · as of 10 Nov 2026
Low 23.00
Mean 28.92
High 32.00
Price 24.49
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Envista Holdings Corporation Logo Envista Holdings Corporation Analysis (NVST)

United States Health Care Official Website Stock

Is Envista Holdings Corporation a good investment? Envista Holdings Corporation (NVST) is currently trading at 24.49 USD. Market analysts have a consensus price target of 28.92 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 6.75. This relatively low multiple may signal that Envista Holdings Corporation is undervalued compared to historical market norms.

Earnings Schedule: Envista Holdings Corporation is expected to release its next earnings report on Feb. 4, 2027. The market consensus estimate for Forward EPS is 1.67.

Investor FAQ

Does Envista Holdings Corporation pay a dividend?

No, it does not currently pay a dividend.

What asset class is Envista Holdings Corporation?

Envista Holdings Corporation is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 4, 2027. The company currently has a trailing EPS of 3.85.

Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products, as well as provides DTX Studio Clinic, a software package offered with its imaging products. This segment offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.

Exchange Ticker
NYQ (United States) NVST
FRA (Germany) 0HV.F
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion